On Nov. 9, 2020, Pfizer and partner BioNTech announced that the vaccine had met the first effectiveness bar in a key study.

On the heels of a production-tinged executive order earlier this month, the Trump administration is doubling down on efforts ...

One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving as later-line therapies to improve survival outcomes. The FDA has also ...